Prima BioMed Ltd
IMMP Healthcare Biotechnology
Prima BioMed Ltd’s revenue for fiscal 2026 (year ended June 2026) was $16.4 million, up 145.2% from fiscal 2025. Revenue growth for three consecutive years.
Follow IMMP
A Cash Flow Statement is a financial report that details the cash inflows and outflows of a company over a specific period. It is divided into three sections: operating activities, investing activities, and financing activities. This statement helps assess the company’s liquidity, solvency, and overall financial health. By tracking cash movements, it provides insights into the company's ability to generate cash to fund operations, pay debts, and invest in growth. Businesses and investors use it to evaluate the sustainability of a company's cash flow and its financial stability.
| Older periods | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|
Operating Cash Flow |
+6 more quarters Free account |
— | — | (18.60) | (18.81) |
Capital expenditures |
(0.05) | (0.01) | (0.01) | (0.06) | |
Investing cash flow |
— | — | (40.92) | 23.19 | |
Other financial activities |
— | — | (0.20) | — | |
Financing cash flow |
— | — | (0.28) | (0.07) | |
Exchange Rate Adjustment |
0.31 | (0.25) | 2.53 | (0.80) | |
Change in Cash |
— | — | (57.27) | 3.51 | |
Beginning Cash |
52.61 | 80.42 | 105.41 | 44.26 | |
Ending Cash |
44.97 | 67.59 | 48.14 | 47.77 | |
Dividends Paid (Common) |
0.00 | 0.00 | 0.00 | 0.00 |